Benzodiazepine tapering: A prospective study
The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benzodiazepines (BZD) are the most widely used sedative-hypnotics, and evidence is rapidly accumulating suggesting potential BZD dependence, association of chronic use with adverse effects and a definite abstinence syndrome produced by withdrawal. AIMS: The present investigation followed prospectively long-term BZD users over 1 year following graded BZD withdrawal in terms of clinical and withdrawal symptoms. METHODS: Clinical symptoms were measured by the Comprehensive Psychopathological Rating Scale (CPRS) and by the Newcastle Anxiety and Depression Diagnostic Index (NADDI) in a sample of BZD users over a 50-week period following graded BZD withdrawal. RESULTS: The results showed that the frequency and severity of clinical symptomatology measured by both scales significantly decreased over time. A detailed analysis of possible patterns of symptoms on both scales revealed four patterns: 1) a gradual decrease over the 50-week time period; 2) an increase in the severity of symptoms at the onset of tapering and a decrease in severity post-tapering; 3) an increase in the severity of symptoms 4 weeks after the cessation of BZD tapering; and 4) no change over the 50-week time period. Rate of BZD withdrawal was associated with CPRS ratings of global illness at admission and at end of treatment, but was not associated with duration or dosage of BZDs, type of BZD, prescriptive and/or non-prescriptive drug use prior to admission, marital status, sex or age. CONCLUSIONS: The results of the present study provide a detailed picture of the pattern of symptoms, their time course and multidimensional determinants of the BZD withdrawal symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients can experience life-threatening withdrawal symptoms with abrupt or rapid discontinuation of BZDs, and some patients experience significant symptoms even with gradual dose reduction.2,20,68”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [68]
In the citing paper
“The population of benzodiazepine patients has been described as a “diagnostically heterogenous group,” which aligns with these results [30,36,40,55,59,65,67].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [67]
In the citing paper
“The most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65]”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [67]
In the citing paper
“Symptoms increased in severity when tapering started and increased to 4 wk post-taper, then reduced”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [67]
Citations
Cites
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,326
The Diagnosis of Depressive Syndromes and the Prediction of E.C.T. Response
Carney, M. W. P., Roth, M., & Garside, R. F. (1965) · British Journal of Psychiatry · doi:10.1192/bjp.111.477.659 · Cited by 936
Jerram, T. C. (1981) · Side Effects of Drugs Annual · doi:10.1016/s0378-6080(81)80009-8 · Cited by 690
Drugs and the treatment of psychiatric disorders
Baldessarini, R. J. (1996) · Medical Entomology and Zoology · Cited by 683
Benzodiazepine use, abuse, and dependence.
O’Brien, C. P. (2005) · PubMed · Cited by 539
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Benzodiazepine withdrawal: an unfinished story.
Ashton, H. (1984) · BMJ · doi:10.1136/bmj.288.6424.1135 · Cited by 291
Hypnotics and sedatives; ethanol
Wr, H. (1996) · Medical Entomology and Zoology · Cited by 275
Gradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271
Research works printed but not linked: 5
- Balter MB, 1991, J Clin Psychiat, 52, 16
- O’Brien CP, 2005, J Clin Psychiatry, 66, 28
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition-revised. Washington, DC: The American Psychiatric Association; 1987.
- Schuetz H, 1982, Aerztliches Laborator, 28, 117
- Vicens C, 2006, Br J Gen Pract, 56, 958
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
“A recent prospective study revealed four patterns of withdrawal symptoms over time [131]: 1 a gradual decrease over the 50-week time-period; 2 an increase in the severity of symptoms at the onset of tapering and a decrease in severity post-tapering; 3 an increase in the severity of symptoms 4 weeks after the cessation…”
BackgroundBenzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Dell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
“A recent prospective study revealed four patterns of withdrawal symptoms over time [177]: a gradual decrease over the 50-week time period; an increase in the severity of symptoms at the onset of tapering and a decrease in severity post-tapering; an increase in the severity of symptoms 4 weeks after the cessation of BZ…”
BackgroundWithdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“2,20,68 As such, it is important for clinicians to adopt a patient-centered approach when considering BZD tapering, acknowledging patient concerns and engaging in a shared decision-making process.”
Stories of Hell and Healing: Internet Users’ Construction of Benzodiazepine Distress and Withdrawal
Fixsen, A. M., & Ridge, D. (2017) · Qualitative Health Research · doi:10.1177/1049732317728053 · Cited by 34
Dependence on Prescription Benzodiazepines and Z-drugs Among Young to Middle-aged Patients in France
Guerlais, M., Grall-Bronnec, M., Feuillet, F., Gérardin, M., Jolliet, P., & Victorri-Vigneau, C. (2015) · Substance Use & Misuse · doi:10.3109/10826084.2014.980952 · Cited by 29
“Many studies explored some BZD/z-drugs dependence criteria, such as the withdrawal syndrome (Ashton, 2005; Barker, Greenwood, Jackson, & Crowe, 2004; Busto & Sellers, 1991a; Schweizer & Rickels, 1998; Urcam Ile de France, 2005; Vikander et al., 2010), the duration of administration (Barker, Greenwood, Jackson, & Crowe…”
BackgroundBourgeois, J., Elseviers, M. M., Azermai, M., Van Bortel, L., Petrovic, M., & Vander Stichele, R. R. (2014) · European Geriatric Medicine · doi:10.1016/j.eurger.2013.11.005 · Cited by 29
“005 the risk of withdrawal effects with temporary worsening of insomnia and anxiety [16,17].”
BackgroundClinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications
Baldwin, D. S. (2022) · Addiction · doi:10.1111/add.15695 · Cited by 28
Issues and controversies surrounding the diagnosis and treatment of social anxiety disorder
Dalrymple, K. L. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.81 · Cited by 22
Marti, J., Bachhuber, M. A., Feingold, J. H., Meads, D. M., Richards, M. R., & Hennessy, S. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016229 · Cited by 21
Fixsen, A. M. (2016) · Qualitative Health Research · doi:10.1177/1049732315576496 · Cited by 17
Zanardi, R., Carminati, M., Fazio, V., Maccario, M., Verri, G., & Colombo, C. (2023) · Pharmaceuticals · doi:10.3390/ph16030426 · Cited by 18
“BDZs cause a positive allosteric modulation of GABAA receptors [22], amplifying the inhibiting effect of the endogenous neurotransmitter and thereby explicating sedative, anxiolytic, and hypnotic effects.”
BackgroundBenzodiazepine absetzen im Alter: Wann und, wenn ja, wie?
Wolter, D. K. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-016-1171-5 · Cited by 16
Carminati, M., Tondello, M., & Zanardi, R. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1471083 · Cited by 13
Basińska-Szafrańska, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03048-y · Cited by 12
Suchtpotenzial und andere Risiken von Benzodiazepinen und Z-Drugs im Alter
Wolter, D. K. (2017) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000474 · Cited by 9
Benzodiazepine Withdrawal: Clinical Aspects
Wright, S. L. (2020) · The Benzodiazepines Crisis · doi:10.1093/med/9780197517277.003.0008 · Cited by 7
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025) · PLOS One · doi:10.1371/journal.pone.0330277 · Cited by 7
“The most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as…”
Medical Complications of Eating Disorders, Substance Use Disorders, and Addictions
Powers, P. S., & Cloak, N. L. (2014) · Springer eBooks · doi:10.1007/978-3-642-45378-6_15 · Cited by 7
Tapering (deprescribing) of benzodiazepine tranquilizers
Sychev, D. A., Zhuchkov, A., Tereshchenko, O. V., & Ivashchenko, D. V. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-1-89-95 · Cited by 5
Allary, A., Proulx-Tremblay, V., Bélanger, C., Hudon, C., O’Connor, K. P., Roberge, P., Vasiliadis, H., Desrosiers, C., Cruz-Santiago, D., & Grenier, S. (2024) · Aging & Mental Health · doi:10.1080/13607863.2024.2372473 · Cited by 3
“The few studies available, in the general population, have found that anxiety and depression diminished after long-term withdrawal (Rickels et al., 1991; Vikander et al., 2010).”
Gozda, K., Leung, J., Baum, L., Singer, A. G., Konrad, G., McMillan, D. E., Falk, J., Kosowan, L., & Leong, C. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01724-9 · Cited by 3
“Withdrawal symptoms include anxiety, depression, agitation, nausea, vomiting, hallucination, hypersensitivity to stimuli, perceptual distortions, depersonalizations, and seizures [1, 4, 5, 15, 16].”
BackgroundGallo, A., MacDonald, T., Bennett, K., Basso-Hulse, G., & Hulse, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195948 · Cited by 2
“the dose over weeks to months, even years; however, this method is still associated with increased anxiety and withdrawal symptoms [16].”
MethodTakamine, L. H., Krein, S. L., Ratliff, E., Strominger, J., Virk, A., & Maust, D. T. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08385-z · Cited by 3
Safety and Tolerability of Anxiolytics/Sedative-Hypnotics
Arcoraci, V., & Spina, E. (2015) · Springer eBooks · doi:10.1007/978-3-319-24741-0_10 · Cited by 2
Vogel, M., & Caflisch, C. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00017-4 · Cited by 2
Carminati, M., Tondello, M., Zappia, M., & Zanardi, R. (2026) · Pharmaceuticals · doi:10.3390/ph19010141 · Cited by 1
“Their clinical properties are mediated primarily through positive allosteric modulation of the GABAA receptor, enhancing inhibitory neuro-transmission and producing anxiolytic, sedative and muscle-relaxant effects [2].”
Vampini, C., & Gallelli, L. (2014) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 1
Balmori, A. A., Álvarez, G. G., Turiel, C. R., Suárez, E. A. P., & Rodríguez, O. W. M. A. A. S. (2018) · Adicciones · doi:10.20882/adicciones.1116 · Cited by 1
Vogel, M., & Caflisch, C. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00014-x · Cited by 2
Substance Withdrawal in ICU Environment
Martínez, N., & Pintado, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-74698-2_143-1 · Cited by 1
EVALUATION OF ANTI ANXIETY ACTIVITY OF BAMBUSA VULGARIS EXTRACTS IN EXPERIMENTAL ANIMALS
Kaur, D., Bains, N., & Chopra, A. (2019) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.1009274 · Cited by 1
From Benzodiazepine Prescription to Dependence: Learning Processes Involved
de la Villarmois, E. A., Constantin, M. F., & Pérez, M. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_19 · Cited by 1
Substance Withdrawal in ICU Environment
Martínez, N., & Pintado, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_143 · Cited by 1
Persistent Postwithdrawal Syndrome after Benzodiazepine Discontinuation. A Reply to Huff
Cosci, F., & Chouinard, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000515015 · Cited by 1
Gozda, K., Leung, J., Baum, L., Singer, A. G., Konrad, G., McMillan, D. E., Falk, J., Kosowan, L., & Leong, C. (2022) · Figshare · doi:10.6084/m9.figshare.19746119
Metadata
- Authors
- Vikander, B., Koechling, U. M., Borg, S., Tönne, U., & Hiltunen, A. J.
- Affiliations
- Karolinska Institutet (SE)
- Karlstad University (SE)
- Corresponding author
- Hiltunen, Arto J.
- Venue
- Nordic Journal of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2010-07-15
- Volume
- 64
- Issue
- 4
- Pages
- 273-282
- ISSN
- 0029-1455 (ISSN-L)
- 0803-9488
- 1502-4725
- OpenAlex
- W2103482466
- Cited by
- 37
- References
- 45
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 3
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nordic Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepine withdrawal, benzodiazepine tapering, withdrawal symptoms, benzodiazepine dependence, sedative-hypnotic drugs, Comprehensive Psychopathological Rating Scale
- MeSH terms
- Adolescent, Adult, Anxiety Disorders, Benzodiazepines, Depressive Disorder, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypnotics and Sedatives, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Substance Withdrawal Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.